ConductScience.org, home

Paper8167351

A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.

Ringdén O and 9 others. Blood, 1994. Cited by 290 papers, by iCite.

Cite this record

ConductScience Library. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Papers, record 8167351. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8167351

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
PubMed
Journal
Blood
PubMed
Year
1994
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
290
iCite
Relative citation ratio, by iCite
9.48
iCite
Revised in PubMed
2021-02-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ringdén OO
2Ruutu TT
3Remberger MM
4Nikoskelainen JJ
5Volin LL
6Vindeløv LL
7Parkkali TT
8Lenhoff SS
9Sallerfors BB
10Ljungman PP

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone Marrow TransplantationMajor topic
BusulfanMajor topic
LeukemiaMajor topic
Whole-Body IrradiationMajor topic
Adolescent
Adult
Cause of Death
Child
Child, Preschool
Cystitis
Cytomegalovirus Infections
Graft vs Host Disease
Hepatic Veno-Occlusive Disease
Humans
Middle Aged
Recurrence

Source PubMed

Download CSV of topics

Cited by104

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 290 citations.

PMIDTitleJournalYearIn PapersSource
41713515
Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report From the National Clinical Trials Network.
Int J Radiat Oncol Biol Phys2026https://conductscience.org/library/papers/41713515PubMed
40399957Improving total bone marrow and lymphoid irradiation: feasibility of intensity-modulated proton therapy (IMPT) and dosimetric comparison with helical tomotherapy (HT).Radiat Oncol2025https://conductscience.org/library/papers/40399957PubMed
36505853Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies.Front Oncol2022https://conductscience.org/library/papers/36505853PubMed
36263219Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review.Front Oncol2022https://conductscience.org/library/papers/36263219PubMed
36084276Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.J Clin Oncol2023https://conductscience.org/library/papers/36084276PubMed
35924145Feasibility of a Novel Sparse Orthogonal Collimator-Based Preclinical Total Marrow Irradiation for Enhanced Dosimetric Conformality.Front Oncol2022https://conductscience.org/library/papers/35924145PubMed
35242706Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse.Front Oncol2022https://conductscience.org/library/papers/35242706PubMed
34956984Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.Front Pediatr2021https://conductscience.org/library/papers/34956984PubMed
34513689Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.Front Oncol2021https://conductscience.org/library/papers/34513689PubMed
34501237The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia.J Clin Med2021https://conductscience.org/library/papers/34501237PubMed
33650334Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation.J Korean Med Sci2021https://conductscience.org/library/papers/33650334PubMed
33544322Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.Int J Hematol2021https://conductscience.org/library/papers/33544322PubMed
33458277Total marrow irradiation for hematopoietic malignancies using volumetric modulated arc therapy: A review of treatment planning studies.Phys Imaging Radiat Oncol2019https://conductscience.org/library/papers/33458277PubMed
33054792Leaf open time sinogram (LOTS): a novel approach for patient specific quality assurance of total marrow irradiation.Radiat Oncol2020https://conductscience.org/library/papers/33054792PubMed
32892216
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT.
Bone Marrow Transplant2021https://conductscience.org/library/papers/32892216PubMed
31675173Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.Clin Transl Sci2020https://conductscience.org/library/papers/31675173PubMed
31647022
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
J Hematol Oncol2019https://conductscience.org/library/papers/31647022PubMed
31536825
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant2020https://conductscience.org/library/papers/31536825PubMed
31473319Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/31473319PubMed
30099836Energy-dependent OAR sparing and dose conformity for total marrow irradiation of obese patients.J Appl Clin Med Phys2018https://conductscience.org/library/papers/30099836PubMed

See all 104 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8167351

GET https://conductscience.org/api/papers/v1/8167351/cited_by?page=2